New mutation L324M in the ABL1 kinase domain: does it confer high resistance to second-generation inhibitors? | ||
| dc.conicet.organizacion | Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas "Mariano R. Castex". Departamento de Genética | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental | |
| dc.conicet.organizacion | Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas "Mariano R. Castex". Departamento de Genética | |
| dc.conicet.organizacion | Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas "Mariano R. Castex". Departamento de Genética | |
| dc.conicet.organizacion | Hospital Británico de Buenos Aires | |
| dc.conicet.organizacion | Consultorios Hematológicos S.R.L. | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental | |
| dc.conicet.organizacion | Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas "Mariano R. Castex". Departamento de Genética | |
| dc.contributor.author | Noriega, Maria Fernanda | |
| dc.contributor.author | Ferri, Cristian Alberto | |
| dc.contributor.author | Icardi, Gustavo | |
| dc.contributor.author | Bullorsky, Eduardo | |
| dc.contributor.author | Korin, Jorge | |
| dc.contributor.author | Larripa, Irene Beatriz | |
| dc.date.issued | 2014-03 | |
| dc.description.abstract | In chronic myeloid leukemia (CML) the presence of mutations in the tyrosine kinase domain (TK) of the normalABL1 gene is the most common cause of loss of response to treatment. Detection of these mutations is an important study because it allows the choice of most suitable TK inhibitor. We report a new mutation L324M that has not been detected so far. It is a case of a 44 year old male with CML chronic phase diagnosis in February 1996, who was treated from 2001 to 2006 with Imatinib. From February 2006 to May 2011 he was treated with decreasing doses of Dasatinib due to intolerance to the drug. At that time the patient showed loss of cytogenetic response and the presence of the mutation L324M by direct sequencing. Because of these finding, treatment was changed to 600 mg/day Nilotinib. After three months of treatment the mutation becomes undetectable and major molecular response (BCR-ABL1<0.1%) was achieved at 12 months. Our data suggest that the L324M mutation is sensitive to Nilotinib treatment. | es |
| dc.description.fil | Fil: Noriega, Maria Fernanda. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas "Mariano R. Castex". Departamento de Genética; Argentina | |
| dc.description.fil | Fil: Ferri, Cristian Alberto. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas "Mariano R. Castex". Departamento de Genética; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina | |
| dc.description.fil | Fil: Icardi, Gustavo. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas "Mariano R. Castex". Departamento de Genética; Argentina | |
| dc.description.fil | Fil: Bullorsky, Eduardo. Hospital Británico de Buenos Aires; Argentina | |
| dc.description.fil | Fil: Korin, Jorge. Consultorios Hematológicos S.R.L.; Argentina | |
| dc.description.fil | Fil: Larripa, Irene Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas "Mariano R. Castex". Departamento de Genética; Argentina | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Noriega, Maria Fernanda; Ferri, Cristian Alberto; Icardi, Gustavo; Bullorsky, Eduardo; Korin, Jorge; et al.; New mutation L324M in the ABL1 kinase domain: does it confer high resistance to second-generation inhibitors?; Taylor & Francis Ltd; Leukemia and Lymphoma; 55; 3; 3-2014; 698-701 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.issn | 1042-8194 | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/102282 | |
| dc.journal.ciudad | Londres | es |
| dc.journal.number | 3 | es |
| dc.journal.pagination | 698-701 | es |
| dc.journal.pais | Reino Unido | es |
| dc.journal.title | Leukemia and Lymphoma | es |
| dc.journal.volume | 55 | es |
| dc.language.iso | eng | es |
| dc.publisher | Taylor & Francis Ltd | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.3109/10428194.2013.810735 | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/abs/10.3109/10428194.2013.810735 | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | * |
| dc.subject | CML | es |
| dc.subject | Mutation | es |
| dc.subject | tyrosine kinase | es |
| dc.subject | Resistance | es |
| dc.subject | tyrosine kinase | es |
| dc.subject.classification | Otras Ciencias de la Salud | es |
| dc.subject.classification | Ciencias de la Salud | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | New mutation L324M in the ABL1 kinase domain: does it confer high resistance to second-generation inhibitors? | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.6635973b-edc4-46f0-b54c-59b7b84cd2be_D.pdf
- Tamaño:
- 396.34 KB
- Formato:
- Adobe Portable Document Format